[Comparision of costs of secondary prevention and treatment of stroke--cost-effectiveness analysis].
نویسندگان
چکیده
UNLABELLED Cerebrovascular accident (CVA) is a serious complication of untreated arterial hypertension. INTRODUCTION The aim of this paper is to compare the cost of secondary prevention and treatment of CVA caused by untreated arterial hypertension. METHODS Cost-effectiveness analysis of diagnosis and therapy of arterial hypertension in comparison with CVA treatment. RESULTS The cost of secondary prevention of CVA per patient per year in 2006. was 1.589,19 kunas, which comes to 15.107,75 kunas in thirty years of treatment (discount factor included), whereas a single CVA treatment was 17.207,54 kunas on average. In every 850 treatments of hypertension (NNT) comes a prevented CVA which is 1.350.811,5 kunas, and is therefore more expensive than a single CVA treatment. CONCLUSION Secondary prevention has a long-term protective effect improving the patients' quality of life, inhibiting the potential post-CVA handicap and pre-retirement. Thus, the main advantage of both primary and secondary prevention is in their greater benefit for patients.
منابع مشابه
Health Technology Assessment of the Psychotherapy Effect on Prevention of Suicide and Self-Harm: A Rapid Review of Secondary Studies
Introduction: According to the World Health Organization (WHO) report, acute depression disorders are the second largest health problem in the world which can cause disability and imposes huge costs on individuals and societies. This study aims to investigate the effectiveness and cost-effectiveness of using psychotherapy in patients with depression for prevention of suicide an...
متن کاملEconomic Evaluation of Infliximab for Treatment of Refractory Ulcerative Colitis in Iran: Cost-Effectiveness Analysis
The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. Hypothetical patients, were individuals with moderate to sev...
متن کاملHealth and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis.
BACKGROUND Whether to cover cardiovascular disease costs is an increasingly pressing question for low- and middle-income countries. We sought to identify the impact of expanding national insurance to cover primary prevention, secondary prevention, and tertiary treatment for cardiovascular disease in India. METHODS AND RESULTS We incorporated data from coverage experiments into a validated mic...
متن کاملEconomic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate.
OBJECTIVE To analyse the economic benefits, in comparison with placebo, of the secondary prevention of ischaemic stroke and myocardial infarction (MI) with lysine acetylsalicylate (Kardégic) in patients with a history of ischaemic stroke, MI or stable and unstable angina pectoris. DESIGN AND SETTING This was a modelling study from the perspectives of direct medical costs, the social security ...
متن کاملCost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
AIMS Treatment guidelines have been developed for both "primary" and "secondary" prevention of coronary heart disease. These should consider both the efficacy as well as the costs of such treatment, particularly the costs of treatment with HMG co-enzyme A reductase inhibitors (statins). In the context of guideline development in The Netherlands, the cost effectiveness of treatment with statins ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Lijecnicki vjesnik
دوره 133 9-10 شماره
صفحات -
تاریخ انتشار 2011